Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.

NCT02179970 is registered in ClinicalTrials.gov with CCTU- Cancer Theme as lead sponsor.

NCT NCT02179970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02179970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.
Lead sponsor
CCTU- Cancer Theme
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
December 14, 2018
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic, ovarian serous adenocarcinoma, pancreatic adenocarcinoma metastatic